Topic: fatty liver disease
While hitting the headlines for its big spending in cancer R&D of late, Gilead is still keeping one eye on its roots in liver disease, penning an early research pact in NASH.
Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.
Pfizer is joining forces with Novartis to treat NASH and try to get a slice of a potentially multibillion-dollar future market.
In mouse models of obesity, the naturally occurring protein FGFBP3 drastically reduced fat mass.
Gemphire is cutting its staff in a bid to cut costs after the FDA requested more preclinical data for its only drug, gemcabene.
Viking Therapeutics’ lead lipid disorder asset met its endpoints in a midstage trial, dropping cholesterol and liver fat levels in patients with NAFLD.
Gemphire is halting a midphase trial testing gemcabene in pediatric nonalcoholic fatty liver disease because some patients’ disease got worse.
Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.
Scientists at Duke have identified a pathway in the liver that they believe could be manipulated to reduce the deposition of fat in the liver, as well as glucose regulation.
The round reunites some of the executives and investors who helped Dezima and Akarna to takeovers by Amgen and Allergan, respectively.